FDA Execs Prefer Novel Switch Model Sans Intervention
This article was originally published in The Tan Sheet
Executive Summary
Leaders at FDA’s drug center appear more closely aligned with the OTC industry than with medical professionals’ groups on consumer access to innovative switches. CDER Director Woodcock says the clinical community has resisted switches – and been proven wrong – before.
You may also be interested in...
Potential OTC Contraception Market Could Attract Switch
A report showed 62.2% of 2,046 women surveyed favor OTC sales of contraception pills, representing a potential U.S. market of around 11 million. The results also could reflect consumer interest in making the drugs available OTC under conditions of safe use.
Potential OTC Contraception Market Could Attract Switch
A report showed 62.2% of 2,046 women surveyed favor OTC sales of contraception pills, representing a potential U.S. market of around 11 million. The results also could reflect consumer interest in making the drugs available OTC under conditions of safe use.
Potential OTC Contraception Market Could Attract Switch
A report showed 62.2% of 2,046 women surveyed favor OTC sales of contraception pills, representing a potential U.S. market of around 11 million. The results also could reflect consumer interest in making the drugs available OTC under conditions of safe use.